Table 2.
Vaccines specific to severe acute respiratory syndrome coronavirus 2 under clinical investigation and their development status
|
Vaccine name
|
Vaccine type
|
Status
|
Registration ID
|
Date of registration
|
Developer
|
| 2019-nCOV | Adenovirus vaccine | Phase II | ChiCTR2000031781 | 10-Apr-20 | Academy of Military Medical Sciences |
| Ad5-nCoV | Adenovirus vaccine | Phase II | NCT04341389 | 10-Apr-20 | CanSino Biologics |
| AV-COVID-19 | Autologous dendritic cells | Phase IB/II | NCT04386252 | 13-May-20 | Aivita Biomedical, Inc |
| BBIBP-CorV | Inactivated virus | Phase I/II | ChiCTR2000032459 | 29-Apr-20 | Beijing Institute of Biological Products & Sinopharm |
| BNT162 | mRNA vaccine | Phase I/II | NCT04380701 | 8-May-20 | BioNTech and Pfizer |
| ChAdOx1 | Adenovirus vaccine | Phase II/III | NCT04400838 | 26-May-20 | University of Oxford |
| Covax-19™ | SARS-CoV-2 spike protein | Phase I | NCT04428073 | 11-Jun-20 | GeneCure Biotechnologies |
| COVID-19/aAPC | Antigen presenting cells | Phase I | NCT04299724 | 9-Mar-20 | Shenzhen Geno-Immune Medical Institute |
| INO-4800 | DNA vaccine | Phase I | NCT04336410 | 7-Apr-20 | Inovio Pharmaceuticals |
| LV-SMENP-DC | Lentiviral vector system | Phase I/II | NCT04276896 | 19-Feb-20 | Shenzhen Geno-Immune Medical Institute |
| mRNA-1273 | mRNA vaccine | Phase II | NCT04405076 | 28-May-20 | ModernaTX, Inc |
| NVX-CoV2373 | Recombinant Spike Protein | Phase I/II | NCT04368988 | 30-Apr-20 | Novavax |
| PiCoVacc | Inactivated virus + adjuvant | Phase I/II | NCT04352608 | 20-Apr-20 | Sinovac |
| V- SARS | Heat-inactivated plasma | Phase I/II | NCT04380532 | 8-May-20 | Immunitor LLC |
| Vero cells | Inactivated virus | Phase I/II | ChiCTR2000031809 | 11-Apr-20 | Wuhan Institute of Biological Products & Sinopharm |
LLC: Lewis lung carcinoma; COVID-19: Coronavirus disease 2019; SARS: Severe acute respiratory syndrome.